Targeting IL-5 pathway against airway hyperresponsiveness: A comparison between benralizumab and mepolizumab.

ABSTRACT:

Background and purpose

Airway hyperresponsiveness (AHR) is a central abnormality in asthma. IL-5 may modulate AHR in animal models of asthma, but the available data is inconsistent on the impact of targeting IL-5 pathway against AHR. The difference between targeting IL-5 or the IL-5 receptor, α subunit (IL-5Rα) in modulating AHR remains to be investigated in human airways. The aim of this study was to compare the role of the anti-IL-5Rα benralizumab and the anti-IL-5 mepolizumab against AHR and to assess whether these agents influence the levels of cAMP.

Experimental approach

Passively sensitized human airways were treated with benralizumab and mepolizumab. The primary endpoint was the inhibition of AHR to histamine. The secondary endpoints were the protective effect against

SUBMITTER: Calzetta L 

PROVIDER: S-EPMC7520436 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature